The NOA project by Eversens S.L. was approved within the call for SME Instrument H2020, Topic SMEInst-01-2016-2017: Open Disruptive Innovation Scheme, Call 2017-02-15.
Thanks to the Phase 1 project granted, Eversens has been able to improve its Feasibility Study.
The Global Burden of Diseases Study indicates that as many as 334 million people in the world have asthma. In Europe, about 30 million children and adults under 45 years old have asthma.
There is no cure for asthma, it is a chronic disease. Asthma can have a very negative impact on the quality of life of those people who suffer from it. However, it can be diagnosed and effectively controlled at an early stage.
We have developed the EverNoa device (called previously NOA), which monitors asthma in a simple, painless, non-invasive and precise way, with accurate and immediate results. The EverNoa is useful for both preventive and post-treatment monitoring.
The basis of the EverNoa device is its ability to measure the Fraction of Exhaled Nitric Oxide (FeNO) of human breath, which is a marker that indicates the existence and extent of inflammation into airways caused by asthma.
The overall objective of the Project is to confirm the business strategy, business model, intellectual property and marketing strategies of the company Eversens, S.L. to enter into the e-health and medical devices sectors, through the EverNoa.
To do so, we have improved our business plan to allows the international business expansion of our company.
The Project has been developed as planned, in terms of deadlines, budgets, actions, and results obtained.
